Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Keeping Track: Approvals Aplenty As FDA Clears Taltz, Cinqair And Anthim

Executive Summary

The latest drug development news and highlights from our FDA Performance Tracker.

You may also be interested in...



Deal Watch: Roche, Pfizer, GSK Close Out 2021 With Licensing Transactions

Ahead of the usual flurry of deal-making in January, Roche gets retinal cell therapy candidate from Lineage Cell Therapeutics, Pfizer subsidiary Amplyx licenses antiviral candidate to Vera, and GSK expands neurology tie-up with Ligand.

Keeping Track: FDA Nixes Medicure’s Aggrastat For STEMI, Approves Insys’ Syndros

The latest drug development news and highlights from our FDA Performance Tracker

Lilly’s Psoriasis Drug Taltz Set For Second Quarter Launch

Ixekizumab had a smooth FDA approval, with no advisory committee needed for the second member of the IL-17 inhibitor class.

Topics

Related Companies

UsernamePublicRestriction

Register

PS057544

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel